The GCC Cancer Vaccine that is being developed recognizes GCC on cancer cells and induces immune responses by activating CD8+T cells and B cells.

Further, the vaccine prevents and treats recurrence and metastasis of GCC-expressing tumors, including colorectal, gastric, pancreatic, and esophageal cancer, by destroying only metastatic cancer cells but not normal cells within the intestine.

 

Orphan drug designation: Can be granted for applications including metastatic colorectal, pancreatic, gastric, and esophageal cancers